Teva Pharmaceutical Industries announced positive results for its Treanda drug trial, for the treatment of lymphoma. During the trial, Treanda was given to patients with slow-growing lymphoma (non-Hodgkin lymphoma), in combination with Roche’s Rituxan. Results showed that patients treated with the combined drugs lived three years longer with no progression of their tumors, compared to those taking chemotherapy with Rituxan.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Satellites To Seek Out Underground Reserves Of Lithium
August 16, 2022

Israel To Launch Renewable Energy Projects In 7 Arab Countries
August 16, 2022

Israeli Secure Enterprise Browser Provider Raises $100M
August 15, 2022

Wiz Becomes World’s Fastest-Growing Software Company
August 15, 2022
Facebook comments